Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated.
<h4>Objectives</h4>To study whether subjects with a molecular genetic diagnosis of familial hypercholesterolemia (FH) or familial defective apoB-100 (FDB) are being adequately treated.<h4>Design</h4>A questionnaire regarding medical history was sent to 2611 subjects who had b...
Guardado en:
Autores principales: | Trond P Leren, Knut Erik Berge |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0ccaae1a7d30491ea711e5eaacb8cc00 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Complex Phenotype of Hypercholesterolemia in a Family with Both ABCG8 and APOB Mutations
por: Ana Cristina Ferreira, et al.
Publicado: (2021) -
Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE-/- mice
por: Pontus Dunér, et al.
Publicado: (2021) -
Increased tau phosphorylation and impaired presynaptic function in hypertriglyceridemic ApoB-100 transgenic mice.
por: Nikolett Lénárt, et al.
Publicado: (2012) -
ApoB100-LDL acts as a metabolic signal from liver to peripheral fat causing inhibition of lipolysis in adipocytes.
por: Josefin Skogsberg, et al.
Publicado: (2008) -
PROPORTION OF PSORIASIS IN FAMILIAL HYPERCHOLESTEROLEMIA
por: Samip Sheth, et al.
Publicado: (2021)